or larger amounts of a single RNA-based drug product. “Speed to clinic for personalized RNA therapies will propel the next wave of growth for emerging RNA medicines,” said Igor Khandros ...

“This signals our entry into the development and acceleration of RNA-based drug products, with flexible, on-demand manufacture of RNA-based drug products and capacity for up to one million doses ...

The startup has created what it says is a “generative AI hub” that biotech and pharma companies can use to accelerate the discovery and development of new, DNA- and RNA-based drugs.

Nearly three decades later, drug makers have developed six ... We developed a novel carbohydrate chemistry-based conjugate ...

Nutcracker Therapeutics’ manufacturing solutions can be scaled for an array of drug discovery needs, from small quantities of many RNA constructs, to large-scale applications, such as GMP-grade ...

The first of its kind, Centillion’s patented BiaB technology offers continuous flow-based manufacture and encapsulation of RNA, more flexibility with higher productivities at smaller footprints. It ...

which improve the stability and cellular uptake of RNA-based drugs. Additionally, the increasing occurrence of chronic and genetic diseases, along with the ability of these therapies to target ...